Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEONARDO trial of plerixafor for severe COVID-19 respiratory failure
NL-OMON51400Phase 2Withdrawn
- Sponsor
- 4Living Biotech
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory decompensation comparing Plerixafor with Placebo (2 arms). Primary endpoint: Need for invasive mechanical ventilation or death by day 28. Planned start Jan 2022; status: withdrawn.
02
Drugs
plerixafor
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory decompensation
Beyond the preview
Go deeper on NL-OMON51400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51400.